B-Cell Lymphomas Coverage from Every Angle
Editor:
Leo I. Gordon, MD, FACP
Advertisement
Advertisement

Available Clinical Trials

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or with Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-Cell NHL
A Phase I, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor T Cells for Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for B-cell Lymphoma.
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in NHL and CLL
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-Cell Lymphoma
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell NHL
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-Cell Non-Hodgkin Lymphoma
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.